Published in BMC Cancer on February 08, 2008
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol (2012) 2.21
Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology (2010) 1.86
Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One (2011) 1.48
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One (2011) 1.48
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem (2008) 1.38
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
Colony-forming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine/acinar colonies in laminin hydrogel. Proc Natl Acad Sci U S A (2013) 1.20
Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells. Elife (2013) 1.19
Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett (2012) 1.16
Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol (2010) 1.14
Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem (2011) 1.14
Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles--a role of the endocytic-exocytic pathway. EMBO Mol Med (2011) 1.12
CD133: to be or not to be, is this the real question? Am J Transl Res (2013) 1.12
Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res (2012) 1.11
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem (2011) 1.08
Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci (2015) 1.05
Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci U S A (2014) 1.03
Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer (2012) 1.02
CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer (2011) 1.02
Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol (2009) 0.99
Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis (2010) 0.95
Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol (2012) 0.95
CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Clin Cancer Res (2014) 0.94
Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. Int J Clin Exp Pathol (2012) 0.94
Genome and transcriptome profiles of CD133-positive colorectal cancer cells. Am J Pathol (2011) 0.92
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem (2011) 0.89
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PLoS One (2012) 0.89
Cancer stem cells and epithelial ovarian cancer. J Oncol (2011) 0.89
Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res (2010) 0.88
Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol (2013) 0.88
Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clin Exp Metastasis (2009) 0.87
Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell (2011) 0.87
Increased expression of DNA repair genes in invasive human pancreatic cancer cells. Pancreas (2011) 0.86
Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) (2012) 0.85
In vitro multilineage differentiation and self-renewal of single pancreatic colony-forming cells from adult C57BL/6 mice. Stem Cells Dev (2014) 0.85
Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol (2015) 0.85
CD133, Selectively Targeting the Root of Cancer. Toxins (Basel) (2016) 0.83
CD133 and membrane microdomains: old facets for future hypotheses. World J Gastroenterol (2011) 0.82
Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema. Lung Cancer (2011) 0.82
Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. PLoS One (2014) 0.81
Mouse tissues express multiple splice variants of prominin-1. PLoS One (2010) 0.80
Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med (2008) 0.79
Is stage-specific embryonic antigen 4 a marker for human ductal stem/progenitor cells? Biores Open Access (2012) 0.79
Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. Int J Clin Exp Pathol (2015) 0.78
Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line. Mol Clin Oncol (2012) 0.78
CD133 expression in normal skin and in epithelial cutaneous tumors. Biomed Res Int (2013) 0.77
Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2. Biomolecules (2015) 0.77
Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma. Oncol Rep (2015) 0.77
Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. Oncotarget (2016) 0.76
Commentary: "prom1 function in development, intestinal inflammation, and intestinal tumorigenesis". Front Oncol (2015) 0.76
Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Mol Cancer (2015) 0.76
Characterization of myelomonocytoid progenitor cells with mesenchymal differentiation potential obtained by outgrowth from pancreas explants. Biotechnol Res Int (2012) 0.76
CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation. Oncotarget (2016) 0.76
Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody. Oncol Lett (2015) 0.75
CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro. Exp Ther Med (2012) 0.75
Monoclonal Antibodies 13A4 and AC133 Do Not Recognize the Canine Ortholog of Mouse and Human Stem Cell Antigen Prominin-1 (CD133). PLoS One (2016) 0.75
Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari". J Breast Cancer (2016) 0.75
DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma. Mediators Inflamm (2016) 0.75
Molecular Imaging with MRI: Potential Application in Pancreatic Cancer. Biomed Res Int (2015) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature (2004) 16.56
Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A (2000) 10.88
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood (1997) 7.84
The stem-cell niche as an entity of action. Nature (2006) 7.73
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood (1997) 5.04
Growth and regeneration of adult beta cells does not involve specialized progenitors. Dev Cell (2007) 4.90
Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A (1997) 4.04
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
CD133: molecule of the moment. J Pathol (2008) 3.58
Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development (2005) 3.57
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46
Asymmetric distribution of the apical plasma membrane during neurogenic divisions of mammalian neuroepithelial cells. EMBO J (2004) 3.41
The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem (2000) 3.33
Isolation of renal progenitor cells from adult human kidney. Am J Pathol (2005) 3.12
Leukocyte polarization in cell migration and immune interactions. EMBO J (1999) 3.08
Epithelial stem cells in vivo. J Cell Sci Suppl (1988) 2.99
Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes (2001) 2.95
The canals of Hering and hepatic stem cells in humans. Hepatology (1999) 2.93
Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer (2005) 2.89
In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest (2003) 2.63
Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci (2005) 2.58
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res (2004) 2.54
Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol (2005) 2.52
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res (2007) 2.34
Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. J Cell Biol (2007) 2.19
Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic (2001) 2.03
A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet (2000) 1.87
Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells (1997) 1.74
Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology (2006) 1.74
Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood (2000) 1.72
Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood (2004) 1.67
Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int (2007) 1.67
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
Pancreatic stem cells. J Pathol (2002) 1.36
A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers. Cancer Cell (2007) 1.32
Polarization of human hematopoietic progenitors during contact with multipotent mesenchymal stromal cells: effects on proliferation and clonogenicity. Stem Cells Dev (2006) 1.21
Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens (2007) 1.17
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer (2007) 1.15
CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells (2005) 1.14
Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver. Hepatology (2005) 1.12
Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. J Cell Sci (1999) 1.10
Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release (2007) 1.09
Focus on molecules: prominin-1 (CD133). Exp Eye Res (2006) 1.05
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Identification and expansion of pancreatic stem/progenitor cells. J Cell Mol Med (2005) 0.96
AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood (1998) 0.89
Regeneration of beta-cells and neogenesis from small ducts or acinar cells promote recovery of endocrine pancreatic function in alloxan-treated rats. Arch Med Res (2004) 0.88
Stem cell concepts. Nouv Rev Fr Hematol (1979) 0.85
Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma. Cancer Sci (2003) 0.83
Are there any stem cells in the pancreas? Pancreas (2005) 0.80
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet (2005) 2.22
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes (2004) 2.10
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res (2010) 2.09
Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A (2009) 1.93
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91
FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes (2011) 1.75
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol (2005) 1.66
Distal phalangeal creases--a distinctive dysmorphic feature in disorders of the RAS signalling pathway? Eur J Med Genet (2007) 1.45
Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41
Disruption of a long distance regulatory region upstream of SOX9 in isolated disorders of sex development. J Med Genet (2011) 1.34
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer (2006) 1.32
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes (2006) 1.20
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes (2003) 1.15
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol (2013) 1.13
Pain management in chronic pancreatitis. Eur J Gastroenterol Hepatol (2002) 1.12
Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes (2007) 1.09
Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One (2009) 1.09
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet (2013) 1.05
Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol (2008) 1.05
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02
Exome sequencing and genetic testing for MODY. PLoS One (2012) 1.00
Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. Med Phys (2013) 1.00
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res (2008) 0.99
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem (2011) 0.99
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. J Clin Endocrinol Metab (2003) 0.98
Pancreatic function in carboxyl-ester lipase knockout mice. Pancreatology (2010) 0.94
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS One (2013) 0.93
Mutations in the VNTR of the carboxyl-ester lipase gene (CEL) are a rare cause of monogenic diabetes. Hum Genet (2009) 0.93
A hepatocyte nuclear factor-4 alpha gene (HNF4A) P2 promoter haplotype linked with late-onset diabetes: studies of HNF4A variants in the Norwegian MODY registry. Diabetes (2006) 0.91
Lymphangiogenesis in colorectal cancer--prognostic and therapeutic aspects. Int J Cancer (2007) 0.91
Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid. Diabetes (2013) 0.90
Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res (2010) 0.90
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem (2011) 0.89
Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int (2008) 0.89
The number of tandem repeats in the carboxyl-ester lipase (CEL) gene as a risk factor in alcoholic and idiopathic chronic pancreatitis. Pancreatology (2012) 0.89
Familial occurrence of neonatal diabetes with duplications in chromosome 6q24: treatment with sulfonylurea and 40-yr follow-up. Pediatr Diabetes (2011) 0.89
Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity-onset diabetes of the young. J Clin Endocrinol Metab (2008) 0.88
Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One (2012) 0.88
Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers. J Clin Pathol (2010) 0.88
Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry. Pediatr Diabetes (2008) 0.86
Influence of laparoscopic cholecystectomy on the prevalence of operations for gallstones in Norway. Eur J Surg (2002) 0.85
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer (2008) 0.85
U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med (2014) 0.85
Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer (2014) 0.84
Evaluation of four novel genetic variants affecting hemoglobin A1c levels in a population-based type 2 diabetes cohort (the HUNT2 study). BMC Med Genet (2011) 0.84
Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res (2013) 0.84
Functional dissection of the HNF-1alpha transcription factor: a study on nuclear localization and transcriptional activation. DNA Cell Biol (2005) 0.83
Quantification of pancreatic function using a clinically feasible short endoscopic secretin test. Pancreas (2013) 0.83
Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3. Diabetes Care (2007) 0.83
MC1R, ASIP, TYR, and TYRP1 gene variants in a population-based series of multiple primary melanomas. Genes Chromosomes Cancer (2012) 0.83
PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest (2016) 0.82
Polygenic risk variants for type 2 diabetes susceptibility modify age at diagnosis in monogenic HNF1A diabetes. Diabetes (2009) 0.82
Severe pancreatic dysfunction but compensated nutritional status in monogenic pancreatic disease caused by carboxyl-ester lipase mutations. Pancreas (2013) 0.81
G protein-coupled receptor agonist-stimulated expression of ATF3/LRF-1 and c-myc and comitogenic effects in hepatocytes do not require EGF receptor transactivation. J Cell Physiol (2004) 0.81
Absence of diabetes and pancreatic exocrine dysfunction in a transgenic model of carboxyl-ester lipase-MODY (maturity-onset diabetes of the young). PLoS One (2013) 0.81
DNA hypomethylation, transient neonatal diabetes, and prune belly sequence in one of two identical twins. Eur J Pediatr (2009) 0.80
Assessment of exocrine pancreatic function by secretin-stimulated magnetic resonance cholangiopancreaticography and diffusion-weighted imaging in healthy controls. J Magn Reson Imaging (2013) 0.79
HNF1B mutation in a Turkish child with renal and exocrine pancreas insufficiency, diabetes and liver disease. Pediatr Diabetes (2011) 0.79
Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies. BMC Endocr Disord (2010) 0.79
The role of pancreatic imaging in monogenic diabetes mellitus. Nat Rev Endocrinol (2011) 0.78
GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation. Biochim Biophys Acta (2012) 0.78
Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations. Diabetes Care (2008) 0.78
Glycogenin-2 is dispensable for liver glycogen synthesis and glucagon-stimulated glucose release. J Clin Endocrinol Metab (2015) 0.78
Is pharmacogenetic CYP2D6 testing useful? Tidsskr Nor Laegeforen (2010) 0.78
Improved diagnostic segregation of mantle cell lymphoma by determination of cyclin D1/D3 expression ratio in formalin-fixed tissue. Diagn Mol Pathol (2009) 0.78
Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma Res (2013) 0.78
Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res (2009) 0.77
Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. APMIS (2013) 0.77
Frequency of somatic BRAF mutations in melanocytic lesions from patients in a CDK4 melanoma family. Pigment Cell Melanoma Res (2013) 0.76
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. BMJ Case Rep (2009) 0.76
pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda. BMC Clin Pathol (2009) 0.76
Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (2003) 0.76
[Tailored medicine or narcissomics?]. Tidsskr Nor Laegeforen (2012) 0.75
[Molecular diagnostics in diabetes mellitus]. Tidsskr Nor Laegeforen (2005) 0.75
Frequencies of KIT and GNAQ mutations in acral melanoma. J Cutan Pathol (2014) 0.75
Internal abdominal hernia. Tidsskr Nor Laegeforen (2017) 0.75
[Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen (2006) 0.75
[Progress in diabetes genetics]. Tidsskr Nor Laegeforen (2010) 0.75